Wave Life Sciences announced continued momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

Wave stands to receive up to $3.3 billion in milestone payments

Wave Life Sciences Ltd., a clinical-stage biotechnology company focused on leveraging RNA medicines to revolutionize human health, has disclosed progress on its premier small interfering RNA (siRNA) and RNA editing platform capabilities. Within its ongoing collaboration with GSK, Wave reports that GSK has chosen the first two programs to advance as development candidates following the successful validation of targets. These programs, operating in hepatology, utilize Wave's next-generation GalNAc-siRNA format. In recognition of this milestone, GSK will provide an initial payment of $12 million to Wave for these oligonucleotide programs.

Dr. Paul Bolno, President and CEO of Wave Life Sciences, remarks, "We've reached an exciting juncture in our collaborative research with GSK, with the selection of the first two programs marking a significant step forward in our joint efforts to introduce revolutionary RNA medicines to patients." He underscores the significance of both programs employing Wave's next-generation siRNA format, highlighting its increasing potential within the broader spectrum of RNA-targeting modalities. Furthermore, Dr. Bolno notes that their collaboration encompasses all wave modalities, including RNA editing, with expectations for additional collaborative opportunities in the coming years. Dr. Bolno also announces progress on Wave's wholly owned INHBE program for obesity, which utilizes the company's next-generation GalNAc-siRNA format and is poised to commence clinical trials in the first quarter of 2025.